SGLT2 抑制剂和心脏纤维化:综合性综述
Paschalis Karakasis1, Panagiotis Theofilis2, Panayotis K Vlachakis2
1Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Current problems in cardiology
|August 6, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂可减少心脏纤维化在各种心脏疾病. 这些药物提供超出血糖控制的潜在抗纤维性益处,影响心力衰竭的进展.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 病理学 病理学 病理学
背景情况:
- 心脏纤维化是心力衰竭和心脏代谢疾病中的心律失常的主要驱动因素.
- -葡萄糖共运输体2 (SGLT2) 抑制剂对心肌结构显示有前途的影响.
- 了解SGLT2抑制剂的抗纤维化机制对于心血管疾病管理至关重要.
研究的目的:
- 审查SGLT2抑制剂在调节心脏纤维化中的机制,转化和临床证据.
- 探索SGLT2抑制剂对不同心血管疾病中的纤维化重塑的影响.
- 讨论SGLT2抑制剂作为精密抗纤维菌疗法的潜力.
主要方法:
- 来自心脏纤维化动物模型的实验数据的合成.
- 分析临床试验数据,包括心脏磁共振成像和生物标志物评估.
- 对研究SGLT2抑制剂对益菌体信号通路和细胞功能的影响的研究的综述.
主要成果:
- 在实验模型中,SGLT2抑制剂通过多种途径一致减轻间歇性和周血管纤维化.
- 临床数据表明,SGLT2抑制剂可以导致心脏纤维化回归,特别是在心力衰竭中,心力衰竭的喷射分数被保存.
- 有证据表明,抗纤维素作用独立于血糖控制和血液动力学变化.
结论:
- SGLT2 抑制剂具有与各种心血管疾病相关的显著抗纤维素特性.
- 需要进一步的研究,以组织学证据验证纤维化回归,并评估长期临床益处.
- 未来的方向包括集成先进的成像和人工智能,以实现个性化的抗纤维菌策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
01:26Heart Failure Drugs: Inotropic Agents
724
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
724
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
01:23Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
258
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
258